Article

Patient Forum in NYC will Focus on Hairy Cell Leukemia

Author(s):

Hairy Cell Leukemia Foundation

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia.

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia. There will be ample time for audience Q&A.

Understanding Hairy Cell Leukemia

When: July 17th at 5:30 pm Eastern

Where: Webster Library, 1465 York Avenue, New York City, NY

Featuring: Dr. Martin Tallman, Memorial Sloan Kettering Cancer Center

Hosted by the Hairy Cell Leukemia Foundation

Advance registration is encouraged: https://www.hairycellleukemia.org/forums

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of an orange background with the words "FDA Approval, developing story."
November 8th 2024

FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL

Darlene Dobkowski, MA
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.
"FDA" text.
November 1st 2024

Oncology Drugs Approved by the FDA in October 2024

Darlene Dobkowski, MA
During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.